Relationships between pathological factors and long-term outcomes in patients enrolled in two prospective randomized controlled trials comparing the efficacy of oral tegafur–uracil with CMF (N·SAS-BC 01 trial and CUBC trial)

被引：0

作者：

Shinji Ohno

Shigehira Saji

Norikazu Masuda

Hitoshi Tsuda

Futoshi Akiyama

Masafumi Kurosumi

Akihiko Shimomura

Nobuaki Sato

Shintaro Takao

Shozo Ohsumi

Yutaka Tokuda

Hideo Inaji

Toru Watanabe

Yasuo Ohashi

机构：

[1] Cancer Institute Hospital of Japanese Foundation for Cancer Research,

[2] Fukushima Medical University,undefined

[3] National Hospital Organization Osaka National Hospital,undefined

[4] National Defense Medical College,undefined

[5] Cancer Institute of the Japanese Foundation for Cancer Research,undefined

[6] Kameda Medical Center,undefined

[7] National Cancer Center Hospital,undefined

[8] Niigata Cancer Center Hospital,undefined

[9] Hyogo Cancer Center,undefined

[10] NHO Shikoku Cancer Center,undefined

[11] Tokai University School of Medicine,undefined

[12] Kaizuka City Hospital,undefined

[13] Hamamatsu Oncology Center,undefined

[14] Chuo University,undefined

来源：

Breast Cancer Research and Treatment | 2021年 / 186卷

关键词：

Tegafur–uracil; CMF; Adjuvant chemotherapy; Breast cancer; Tumor-infiltrating lymphocyte;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：135 / 147

页数：12

共 272 条

[1]

Kasumi F(2003)Meta-analysis of five studies on tegafur plus uracil (UFT) as post-operative adjuvant chemotherapy for breast cancer Oncology 64 146-153

[2]

Yoshimoto M(2005)Postoperative adjuvant therapy with tamoxifen, tegafur plus uracil, or both in women with node-negative breast cancer: a pooled analysis of six randomized controlled trials J Clin Oncol 23 2172-2184

[3]

Uchino J(2009)Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial J Clin Oncol 27 1368-1374

[4]

Abe R(2009)Uracil-tegafur and tamoxifen vs cyclophosphamide, methotrexate, fluorouracil, and tamoxifen in post-operative adjuvant therapy for stage I, II, or IIIA lymph node-positive breast cancer: a comparative study Br J Cancer 101 598-604

[5]

Nomura Y(2010)Efficacy of oral tegafur-uracil (UFT) as adjuvant therapy as compared with classical cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in early breast cancer: a pooled analysis of two randomized controlled trials (N·SAS-BC 01 trial and CUBC trial) Breast Cancer Res Treat 119 633-641

[6]

Sugimachi K(2019)Long-term follow-up of two randomized controlled trials (N-SAS-BC01 trial and CUBC trial) comparing oral tegafur-uracil (UFT) versus classical cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) as adjuvant therapy in early breast cancer Cancer Res SABCS 28 1700-1712

[7]

Nakazato H(2017)De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017 Ann Oncol 31 3997-4013

[8]

Abe O(2013)American Society of Clinical Oncology; College of American Pathologists Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update J Clin Oncol 28 486-491

[9]

Noguchi S(1998)Establishment of histological criteria for high-risk node-negative breast carcinoma for a multi-institutional randomized clinical trial of adjuvant therapy. Japan National Surgical Adjuvant Study of Breast Cancer (NSAS-BC) Pathology Section Jpn J Clin Oncol 19 403-410

[10]

Koyama H(1991)Pathological prognostic factors in breast cancer I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up Histopathology 26 259-271

← 1 2 3 4 5 6 7 8 9 10 →